Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
The Food and Drug Administration has granted approval for the next-generation anticlotting medication Eliquis, the regulator announced in a news release. The drug, administered in the form of a pill, is used to reduce stroke risk and fight clotting in patients with atrial fibrillation. This is a common variety of abnormal heart rhythm.
Eliquis has been developed jointly by Pfizer (NYSE: PFE ) and Bristol-Myers Squibb (NYSE: BMY ) .
The new drug is seen as a replacement for wafarin, the current standard treatment for the disorder. It is difficult to determine the precise dose for wafarin, however, and the side effects can be extreme.
It is estimated that over 3 million people in the U.S. and around 8 million throughout the world suffer from atrial fibrillation. It is one of the top causes of stroke.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.